Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity. 2014

Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, People's Republic of China.

A series of 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety (3a-3r) has been designed, synthesized and their biological activities were also evaluated as potential antiproliferation and focal adhesion kinase (FAK) inhibitors. Among all the compounds, 3p showed the most potent activity in vitro which inhibited the growth of A549 with IC50 value of 3.11 μM and Hela with IC50 value of 2.54 μM respectively. Compound 3p also exhibited significant FAK inhibitory activity (IC50=0.45 μM). Docking simulation was performed for compound 3p into the FAK structure active site to determine the probable binding model.

UI MeSH Term Description Entries
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004146 Dioxanes Compounds that contain the structure 1,4-dioxane.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
July 2013, Bioorganic & medicinal chemistry,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
November 2011, Bioorganic & medicinal chemistry,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
October 2011, Bioorganic & medicinal chemistry letters,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
October 2013, European journal of medicinal chemistry,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
January 2020, Bioorganic chemistry,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
May 2012, Bioorganic & medicinal chemistry,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
May 2016, Bioorganic & medicinal chemistry letters,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
June 2019, Acta chimica Slovenica,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
March 2024, ACS omega,
Yong-Tao Duan, and Yong-Fang Yao, and Wei Huang, and Jigar A Makawana, and Shashikant B Teraiya, and Nilesh J Thumar, and Dan-Jie Tang, and Xiang-Xiang Tao, and Zhong-Chang Wang, and Ai-Qin Jiang, and Hai-Liang Zhu
August 2012, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!